Malaria Vaccines: AMA1-rEPA/ALHYDROGEL + CPG 7909

疟疾疫苗开发处总体描述：疟疾疫苗开发处是NIAID的一项倡议，与DMID密切合作，以应对全球对疟疾疫苗的需求。疟疾疫苗开发处于2001年受命研究、开发和生产疟疾疫苗原型，并对有希望的候选疫苗进行早期临床试验。我们的首要目标是研制疟疾疫苗，以减少非洲儿童的严重疾病和死亡，并在世界低传播地区消除疟疾。

Malaria Vaccine Development Branch (MVDB) General Description: The Malaria Vaccine Development Branch (MVDB) is an NIAID initiative working in close collaboration with DMID to respond to the global need for vaccines against malaria. The Malaria Vaccine Development Branch (MVDB) was commissioned in 2001 to research, develop, and produce prototype malaria vaccines and conduct early-phase clinical trials of promising vaccine candidates. Our overarching goal is to develop malaria vaccines that will reduce severe disease and death among African children and eliminate malaria from low-transmission areas of the world. An asexual blood-stage vaccine will elicit immune responses capable of either destroying malaria parasites in the blood stream or inhibiting parasites from infecting red blood cells. In either case, the net effect is to reduce or prevent burden of parasites and hence decrease the incidence, severity, or the complications of disease. Such a vaccine would target blood-stage parasite proteins since these antigens are abundantly expressed by parasites during persistent infections. It would act to prime the immune system for subsequent infection in infants or it would boost already present, yet weak, natural immunity in young children. Furthermore, a vaccine composed of multiple antigens will increase the number of individuals responding to at least one component of the vaccine. The inclusion of multiple alleles of polymorphic proteins would also minimize immune pressure on parasite selection, thus decreasing the likelihood of parasite breakthrough.